Freeze-dried PCR reagent and kit for nucleic acid and gene mutation site detection
The lyophilized PCR reagents and kits prepared by lyophilization treatment, combined with an optimized buffer system and mutant Taq DNA polymerase, solves the problems of long detection time and high cost in the prior art, and achieves a fast and sensitive Mycoplasma pneumoniae Diagnosis of drug resistance.
Patent Information
- Application Number
- CN202411157064.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing Mycoplasma pneumoniae detection methods cannot identify pathogens and drug resistance at the same time, and traditional drug sensitivity experiments are time-consuming and are not suitable for early diagnosis and drug guidance. Liquid reagents need to be transported and preserved at low temperatures, and are cumbersome to configure and costly.
A lyophilized PCR reagent and kit was developed, including an optimized buffer system, Taq DNA polymerase, dNTP and specific amplification primers and fluorescent probes. The stable components at room temperature were prepared by lyophilization, using mutant models. Taq DNA polymerase and human genomic β-actin genes are used as internal standards to simplify the detection process.
It reduces detection time, improves detection sensitivity, reduces reagent preparation steps, reduces transportation and storage costs, simplifies the clinical testing process, and can quickly complete the diagnosis of Mycoplasma pneumoniae infection and drug resistance.
Smart Images

Figure CN118932029A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biological detection, and in particular relates to a freeze-dried PCR reagent and a kit for detecting nucleic acid and gene mutation sites. Background Art
[0002] Mycoplasma pneumoniae is a type of prokaryotic cell-type organism that is between bacteria and viruses and has no cell wall. It is an important pathogen that causes tracheitis, bronchitis, and atypical pneumonia in children, and is also one of the most common pathogens that cause community-acquired pneumonia in adults. It has been confirmed that target changes caused by gene point mutations are the most important cause of Mycoplasma pneumoniae's resistance to macrolides. Mycoplasma pneumoniae's resistance to macrolides is mainly related to point mutations in the V region of its 23SrRNA gene, with A2063G and A2064G mutations being the most common. Clinically, it has been confirmed that patients with Mycoplasma pneumoniae that are resistant to macrolides have a prolonged clinical course and worsening of their condition. Therefore, detection of Mycoplasma pneumoniae resistance mutation sites can assist in clinical early warning and screening of high-risk severe cases, and at the same time provide a strong basis for formulating diagnosis and treatment plans.
[0003] Currently, traditional detection of Mycoplasma pneumoniae is mainly based on serology and culture methods, and traditional detection methods can only identify pathogens but cannot simultaneously detect drug resistance; methodological limitations make it unsuitable for large-scale clinical applications; and traditional drug sensitivity tests are usually time-consuming and more suitable for retrospective diagnosis and research, but not suitable for early diagnosis and medication guidance.
[0004] At present, there are multiplex fluorescence quantitative PCR to detect Mycoplasma pneumoniae nucleic acid and its drug-resistant mutations. For example, Chinese patent application CN106191239 discloses a primer, probe, method and kit for real-time fluorescence PCR detection of Mycoplasma pneumoniae nucleic acid and drug-resistant mutations, and CN113462794 discloses a kit and a detection method for detecting Mycoplasma pneumoniae nucleic acid and the presence or absence of drug-resistant gene mutations. The above methods all use exogenous internal standards and cannot monitor the sample collection situation; the detection time is long, which is not conducive to quickly obtaining the test results and delays the diagnosis and treatment time; and all use liquid reagents, containing temperature-sensitive Taq enzymes, primers, probes and other components, which need to be transported and stored at low temperatures to avoid changes in their properties and failure. The configuration is cumbersome during use, and the cost of product storage and transportation is high.
[0005] To this end, the present invention provides a freeze-dried PCR reagent and a kit for detecting nucleic acid and gene mutation sites. Summary of the invention
[0006] In order to make up for the deficiencies of the prior art, at least one technical problem raised in the background technology is solved.
[0007] The technical solution adopted by the present invention to solve the technical problem is: a freeze-dried PCR reagent for nucleic acid and gene mutation site detection according to the present invention comprises:
[0008] MP reaction lyophilized powder;
[0009] MP positive control;
[0010] MP negative control;
[0011] The MP reaction lyophilized powder includes an optimized buffer system, Taq DNA polymerase, dNTP, and a lyophilization protective agent;
[0012] It also includes an oligonucleotide upstream primer (SEQ ID NO: 1), an oligonucleotide downstream primer (SEQ ID NO: 2), and an oligonucleotide fluorescent probe (SEQ ID NO: 3) for specifically amplifying the Mycoplasma pneumoniae P1 gene; an oligonucleotide upstream primer (SEQ ID NO: 4), an oligonucleotide downstream primer (SEQ ID NO: 5), and an oligonucleotide fluorescent probe (SEQ ID NO: 6) for specifically amplifying the 23SrRNA gene mutation site; and an oligonucleotide upstream primer (SEQ ID NO: 7), an oligonucleotide downstream primer (SEQ ID NO: 8), and an oligonucleotide fluorescent probe (SEQ ID NO: 9) for specifically amplifying the β-actin gene on the human genome.
[0013] Preferably, the two ends of the oligonucleotide fluorescent probe are respectively labeled with a fluorescent group and a quenching group, the fluorescent group is one of FAM, VIC, CY5, ROX or other fluorescent groups with luminescent properties, and the quenching group is one of BHQ1, BHQ2, BHQ3, TAMRA, MGB or other chemical groups with fluorescence quenching function.
[0014] Preferably, each tube of the MP reaction lyophilized powder comprises: 0.1 μM to 1 μM oligonucleotide upstream primer, 0.1 μM to 1 μM oligonucleotide downstream primer, 0.1 μM to 1 μM oligonucleotide fluorescent probe, 0.1 to 1 unit Taq DNA polymerase and 1% to 10% m / v lyophilization protectant, 0.1 to 1 mM dNTP and optimized 1 to 10× buffer system.
[0015] Preferably, the Taq DNA polymerase is a mutant Taq DNA polymerase, and the Taq DNA polymerase is one of chemically modified, antibody modified, and ligand modified.
[0016] Preferably, the lyoprotectant is a mixture of one or more of glycine, trehalose, sucrose, gelatin, PEG-20000, hydroxypropyl-β-cyclodextrin, PVP-10000, maltodextrin, sodium carboxymethyl cellulose, etc.
[0017] Preferably, the MP reaction freeze-dried powder is prepared by the following freeze-drying procedure: 0°C, 30 min; -50°C, 3 h; -30°C, 14 bar, 3 h; -10°C, 14 bar, 2 h; 0°C, 14 bar, 1 h; 30°C, 14 bar, 4 h.
[0018] Preferably, the MP positive control is a pseudovirus containing a Mycoplasma pneumoniae P1 gene sequence and a 23S rRNA mutation site gene sequence specific fragment, a pseudovirus containing a human β-actin gene specific fragment, and 0.9% saline, wherein the saline contains 0.1 ng / μL salmon sperm DNA, and the pseudovirus concentration is 10 5 copies / mL.
[0019] Preferably, the MP negative control is a pseudovirus containing a human β-actin gene specific fragment, 0.9% saline, the saline contains 0.1 ng / μL salmon sperm DNA, and the pseudovirus concentration is 10 5 copies / mL.
[0020] Preferably, the quantitative PCR program of the fluorescent group is set as follows: pre-denaturation at 95°C for 30s, denaturation at 95°C for 10s, annealing and extension at 62°C to collect fluorescence for 13s, and this is repeated for 42 cycles. The P1 gene is detected in the ROX channel, the 23S rRNA gene is detected in the FAM channel, and the human β-actin gene is detected in the VIC channel.
[0021] Preferably, a kit for detecting nucleic acid and gene mutation sites is provided, wherein the kit is used for MP reaction lyophilized powder, MP positive control and MP negative control, and the kit is provided with multiple components for the entire detection process of sample collection, nucleic acid extraction and amplification detection.
[0022] The beneficial effects of the present invention are as follows:
[0023] 1. The freeze-dried PCR reagent and kit for detecting nucleic acid and gene mutation sites described in the present invention are prepared by screening out a suitable freeze-dried powder for MP reaction, and oligonucleotide primers and probes of each target and internal standard, Taq DNA polymerase, dNTP, freeze-dried protective agent, optimized buffer system and other components are prepared by a freeze dryer into components that can coexist stably at room temperature, and the detection performance is consistent with that of liquid reagents; the transportation and storage costs of fluorescent PCR reagents are greatly reduced; the flexibility of sample volume is increased, and the detection sensitivity is improved; the reagent preparation steps are reduced, the clinical detection process is simplified, and it is more convenient for practical use and promotion.
[0024] 2. The freeze-dried PCR reagent and kit for detecting nucleic acid and gene mutation sites described in the present invention can monitor the entire detection process including sample collection, nucleic acid extraction and amplification detection by using the conserved region sequence of the β-actin gene on the human genome as the internal standard of the kit, thereby avoiding false negative results caused by sampling, extraction or amplification failure.
[0025] 3. The freeze-dried PCR reagent and kit for detecting nucleic acid and gene mutation sites described in the present invention use mutant antibody-modified Taq DNA polymerase, which can quickly release enzyme activity at 95°C. Combined with a shorter amplicon, the detection time can be greatly shortened, and the detection can be completed in about 40 minutes. The clinical auxiliary diagnosis of Mycoplasma pneumoniae infection and drug resistance can be quickly completed without age or gender restrictions, providing a reference for clinicians to evaluate the drug resistance characteristics of Mycoplasma pneumoniae in individuals. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] The present invention will be further described below in conjunction with the accompanying drawings.
[0027] Figure 1 This is a schematic diagram comparing the appearance of MP anti-freeze-dried powder prepared by different freeze-dried protective agent formulas in one embodiment of the present invention;
[0028] Figure 2 It is a schematic diagram comparing the detection performance of MP reaction lyophilized powder and liquid control in one embodiment of the present invention;
[0029] Figure 3 is a schematic diagram of clinical sample test results in one embodiment of the present invention;
[0030] Figure 4 is a schematic diagram of the stability test results of the kit in one embodiment of the present invention; DETAILED DESCRIPTION
[0031] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further explained below in conjunction with specific implementation methods.
[0032] like Figures 1 to 4 As shown, a freeze-dried PCR reagent for detecting nucleic acid and gene mutation sites described in an embodiment of the present invention includes: MP reaction freeze-dried powder; MP positive control; MP negative control; the MP reaction freeze-dried powder includes an optimized buffer system, Taq DNA polymerase, dNTP, and a freeze-dried protective agent; and also includes an oligonucleotide upstream primer (SEQ ID NO: 1) and an oligonucleotide downstream primer (SEQ ID NO: 2) and an oligonucleotide fluorescent probe (SEQ ID NO: 3) for specifically amplifying the Mycoplasma pneumoniae P1 gene; an oligonucleotide upstream primer (SEQ ID NO: 4) and an oligonucleotide downstream primer (SEQ ID NO: 5) and an oligonucleotide fluorescent probe (SEQ ID NO: 6) for specifically amplifying the 23S rRNA gene mutation site; an oligonucleotide upstream primer (SEQ ID NO: 7) and an oligonucleotide downstream primer (SEQ ID NO: 8) and an oligonucleotide fluorescent probe (SEQ ID NO: 9) for specifically amplifying the β-actin gene on the human genome.
[0033] The MP reaction lyophilized powder provided by the present invention is prepared by screening out a suitable lyophilization protectant formula to prepare the MP reaction lyophilized powder, and oligonucleotide primers and probes of each target and internal standard, Taq DNA polymerase, dNTP, lyophilization protectant, optimized buffer system and other components are prepared by a lyophilizer into components that stably coexist at room temperature, and the detection performance is consistent with that of liquid reagents; the transportation and storage costs of fluorescent PCR reagents are greatly reduced; the flexibility of sample volume is increased, and the detection sensitivity is improved; the reagent preparation steps are reduced, the clinical detection process is simplified, and practical use and promotion are more convenient.
[0034] Furthermore, the two ends of the oligonucleotide fluorescent probe are respectively labeled with a fluorescent group and a quenching group, the fluorescent group is one of FAM, VIC, CY5, ROX or other fluorescent groups with luminescent properties, and the quenching group is one of BHQ1, BHQ2, BHQ3, TAMRA, MGB or other chemical groups with fluorescence quenching function.
[0035] When the fluorescent group provided by the present invention is used, the present invention uses ABIQ5 detection, pre-denaturation at 95°C for 30s, denaturation at 95°C for 10s, annealing and extension at 62°C to collect fluorescence for 13s, and 42 cycles are performed. The P1 gene is detected in the ROX channel, the 23S rRNA gene is detected in the FAM channel, and the human β-actin gene is detected in the VIC channel.
[0036] Furthermore, each tube of the MP reaction lyophilized powder includes: 0.4 μM oligonucleotide upstream primer, 0.4 μM oligonucleotide downstream primer, 0.2 μM oligonucleotide fluorescent probe, 0.6 units of Taq DNA polymerase, m / v 1.5% lyophilization protectant, 0.6 mM dNTP and optimized 5× buffer system.
[0037] Furthermore, the Taq DNA polymerase is a mutant antibody-modified Taq DNA polymerase.
[0038] The Taq DNA polymerase provided by the present invention, when in use, uses a mutant antibody to modify the Taq DNA polymerase, and the enzyme can quickly release enzyme activity under 95° C. Combined with a shorter amplicon, the detection time can be greatly shortened, and the detection can be completed in about 40 minutes. The clinical auxiliary diagnosis of Mycoplasma pneumoniae infection and drug resistance can be quickly completed without being restricted by age or gender, and a reference is provided for clinicians to evaluate the drug resistance characteristics of Mycoplasma pneumoniae in individuals.
[0039] Furthermore, the freeze-drying protective agent is 1.5% sucrose, 1.5% trehalose, 1.5% glycine, and 1.5% maltodextrin.
[0040] Furthermore, the MP reaction freeze-dried powder is prepared by the following freeze-drying procedure: 0°C, 30 min; -50°C, 3 h; -30°C, 14 bar, 3 h; -10°C, 14 bar, 2 h; 0°C, 14 bar, 1 h; 30°C, 14 bar, 4 h.
[0041] Furthermore, the MP positive control is a pseudovirus containing a Mycoplasma pneumoniae P1 gene sequence and a 23S rRNA mutation site gene sequence specific fragment, a pseudovirus containing a human β-actin gene specific fragment, and 0.9% saline, wherein the saline contains 0.1 ng / μL salmon sperm DNA, and the pseudovirus concentration is 10 5 copies / mL.
[0042] Furthermore, the MP negative control is a pseudovirus containing a human β-actin gene specific fragment, 0.9% saline, the saline contains 0.1 ng / μL salmon sperm DNA, and the pseudovirus concentration is 10 5 copies / mL.
[0043] Furthermore, the quantitative PCR program of the fluorescent group was set as follows: pre-denaturation at 95°C for 30s, denaturation at 95°C for 10s, annealing and extension at 62°C to collect fluorescence for 13s, and this was repeated for 42 cycles. The P1 gene was detected in the ROX channel, the 23S rRNA gene was detected in the FAM channel, and the human β-actin gene was detected in the VIC channel.
[0044] Furthermore, a kit for detecting nucleic acid and gene mutation sites is provided, wherein the kit is used for MP reaction lyophilized powder, MP positive control and MP negative control, and the kit is provided with multiple components for the entire detection process of sample collection, nucleic acid extraction and amplification detection.
[0045] When the kit provided by the present invention is used, the conserved region sequence of the β-actin gene on the human genome is used as the internal standard of the kit, and the entire detection process including sample collection, nucleic acid extraction and amplification detection can be fully monitored to avoid false negative results caused by sampling, extraction or amplification failure.
[0046] Working principle:
[0047] Embodiment 1:
[0048] Design of primers and probes for target and internal standard:
[0049] Search the Mycoplasma pneumoniae P1 gene and 23S rRNA gene sequences and human β-actin gene sequences on NCBI, and design specific primers and probe sequences according to the primer and probe design principles. After sequence synthesis, quality inspection and quantification are performed, and then diluted to the required concentration as needed. The primer and probe sequences of the target and internal standard used in the present invention are shown in the following table;
[0050]
[0051]
[0052] Embodiment 2:
[0053] Lyoprotectant screening
[0054] The freeze-dried protective agent formula is as follows:
[0055]
[0056] According to the freeze-dried protective agent formula, the freeze-dried protective agent mother solutions were prepared respectively: Formula 1: 15% (m / v) (sucrose + trehalose); Formula 2: 15% (m / v) (sucrose + trehalose + maltodextrin); Formula 3: 15% (m / v) (sucrose + trehalose + glycine); Formula 4: 15% (m / v) (sucrose + trehalose + glycine + maltodextrin).
[0057] MP reaction lyophilized powder is prepared as follows:
[0058]
[0059]
[0060] After mixing the above components evenly, the MP reaction lyophilized powder with a final reaction volume of 25 μL was obtained. The required volume of mixed solution (25 μL×N) was prepared according to the needs, mixed evenly and dispensed into 8 strips of PCR tubes, and placed in a freeze dryer without covering to prepare the MP reaction lyophilized powder, according to the following procedures: 0℃, 30min; -50℃, 3h; -30℃, 14bar, 3h; -10℃, 14bar, 2h; 0℃, 14bar, 1h; 30℃, 14bar, 4h. After the freeze drying is completed, cover the PCR tube cap and vacuum seal it with an aluminum foil bag (with desiccant inside) to obtain the MP reaction lyophilized powder.
[0061] ① Such as Figure 1 As shown, the appearance morphology of the MP reaction freeze-dried powder prepared by each freeze-dried protectant formula is compared. The MP reaction freeze-dried powder prepared by freeze-dried protectant formula 3 and formula 4: the contents should be lumps, without obvious shrinkage, liquefaction and empty tubes; the volume distribution of the freeze-dried powder is uniform, the same as the volume before freeze-drying, and meets the appearance morphology standards.
[0062] ② Compare the MP reaction freeze-dried powder with qualified appearance and liquid amplification system:
[0063] MP reaction lyophilized powder: MP reaction lyophilized powder + 10μL test sample + 15μL ddH2O;
[0064] Liquid amplification system: Prepare the liquid amplification system according to the table below, vortex to mix, and dispense 15 μL / well.
[0065] Components Amount per person (μL) Final concentration MP-P1-F (100 μM) 0.1 0.4μM MP-P1-R (100 μM) 0.1 0.4μM MP-P1-P (100 μM) 0.05 0.2μM MP-23S-F(100μM) 0.1 0.4μM MP-23S-R (100μM) 0.1 0.4μM MP-23S-P (100μM) 0.05 0.2μM Actin-F (100 μM) 0.1 0.4μM Actin-R (100 μM) 0.1 0.4μM Actin-P (100μM) 0.05 0.2μM Lyophilized Protectant Stock Solution (15%) 2.5 1.5% TaqDNA polymerase (5 units) 3 0.6 units dNTP(10mM) 1.5 0.6mM Optimized 5× buffer system 5 1× ddH2O 2.25 / template 10 / Total 25
[0066] Template: MP Positive control: pseudovirus containing the P1 gene sequence of Mycoplasma pneumoniae and the specific fragment of the 23S rRNA mutation site gene sequence, and pseudovirus containing the specific fragment of the human β-actin gene, 0.9% saline (containing 0.1 ng / μL salmon sperm DNA), pseudovirus concentration of 10 5 MP negative control: pseudovirus containing human β-actin gene specific fragment, 0.9% saline (containing 0.1ng / μL salmon sperm DNA), pseudovirus concentration of 10 5 copies / mL; the nucleic acid of the above template was extracted using the nucleic acid extraction or purification reagent produced by Jiangsu Kangwei Century Biotechnology Co., Ltd., and the nucleic acid extraction was performed according to its instructions.
[0067] Using Applied Biosystems QuantStudio TM5 Real-time fluorescence quantitative PCR instrument was used for detection, and the program was set as follows: in Fast mode, pre-denaturation at 95°C for 30 s, denaturation at 95°C for 10 s, annealing and extension at 62°C to collect fluorescence for 13 s, and this was repeated for 42 cycles. The P1 gene was detected in the ROX channel, the 23S rRNA gene was detected in the FAM channel, and the human β-actin gene was detected in the VIC channel.
[0068] like Figure 2 As shown, the detection performance of the MP reaction lyophilized powder prepared by lyophilized protectant formula 4 is better than that of the MP reaction lyophilized powder prepared by lyophilized protectant formula 3, and is consistent with the detection performance of the liquid control system, and can be used as a lyophilized protectant formula for MP reaction lyophilized powder.
[0069] Embodiment 3:
[0070] Preparation of freeze-dried PCR reagents and kits for detecting Mycoplasma pneumoniae nucleic acid and 23S rRNA gene mutation sites (48 doses / kit);
[0071] (1) MP reaction freeze-dried powder
[0072] Prepare 15% (m / v) (sucrose + trehalose + glycine + maltodextrin). Here, m / v refers to mass concentration, which means the mass per unit volume, and the unit is "kg / L" or "kg / m 3 ”.
[0073] MP reaction lyophilized powder is prepared as follows:
[0074]
[0075]
[0076] After mixing the above components evenly, the MP reaction lyophilized powder with a final reaction volume of 25 μL was obtained. The required volume of mixed solution (25 μL×N) was prepared according to the needs, mixed evenly and dispensed into 8 strips of PCR tubes, and placed in a freeze dryer without covering to prepare the MP reaction lyophilized powder, according to the following procedures: 0℃, 30min; -50℃, 3h; -30℃, 14bar, 3h; -10℃, 14bar, 2h; 0℃, 14bar, 1h; 30℃, 14bar, 4h. After the freeze drying is completed, cover the PCR tube cap and vacuum seal it with an aluminum foil bag (with desiccant inside) to obtain the MP reaction lyophilized powder.
[0077] (2) Positive control: pseudovirus containing the Mycoplasma pneumoniae P1 gene sequence and the 23S rRNA mutation site gene sequence specific fragment and pseudovirus containing the human β-actin gene specific fragment, 0.9% saline (containing 0.1 ng / μL salmon sperm DNA), pseudovirus concentration of 105 copies / mL.
[0078] (3) Negative control: pseudovirus containing human β-actin gene specific fragment, 0.9% saline (containing 0.1 ng / μL salmon sperm DNA), pseudovirus concentration of 105 copies / mL.
[0079] The components of the kit (48 servings / box) are as follows:
[0080]
[0081]
[0082] Embodiment 4:
[0083] Detection process of freeze-dried PCR reagents and kits for detecting Mycoplasma pneumoniae nucleic acid and 23S rRNA gene mutation sites:
[0084] (1) Sample processing: Take 200 μL of the sample to be tested, MP positive control, and MP negative control. It is recommended to use the nucleic acid extraction or purification reagents produced by Jiangsu Kangwei Century Biotechnology Co., Ltd. and perform nucleic acid extraction according to the instructions.
[0085] (2) Sample addition: ① Preparation of reaction solution: Calculate the number of reactions required according to the number of samples to be tested. If the number of samples is n, then the total number of reactions N = n + 2. Take N tubes of MP reaction lyophilized powder and centrifuge them for 30 seconds to ensure that the reaction lyophilized powder is at the bottom of the tube and set aside;
[0086] ② Sample addition: Gently open the cap of the eight-tube strip containing the lyophilized powder, transfer 25 μL of the extracted nucleic acid of the sample to be tested, MP positive control and MP negative control to the eight-tube strip, and cover the cap tightly;
[0087] ③ Vortex for 30 seconds until completely dissolved and the solution is clear with no white lyophilized residue remaining, remove bubbles and centrifuge for 30 seconds for later use.
[0088] (3) PCR amplification: The present invention uses ABIQ5 detection, and in Fast mode, pre-denaturation at 95°C for 30 s, denaturation at 95°C for 10 s, annealing and extension at 62°C, and fluorescence collection for 13 s, for 42 cycles. The P1 gene is detected in the ROX channel, the 23S rRNA gene is detected in the FAM channel, and the human β-actin gene is detected in the VIC channel.
[0089] (4) Result analysis:
[0090] ①Quality control standards:
[0091] MP positive control: The Ct value of the corresponding target of FAM, ROX, and VIC channels should be ≤35;
[0092] MP negative control: FAM channel should have no amplification curve (No Ct) or Ct value>39; ROX channel should have no amplification curve (NoCt) or Ct value>40; VIC channel corresponding target Ct value should be ≤35;
[0093] The above requirements must be met simultaneously in the same experiment, otherwise the experiment will be invalid and must be retested.
[0094] ②Result determination
[0095]
[0096] Note 1: For samples with an obvious S-shaped amplification curve in the FAM channel (Ct value ≤ 39) or (and) ROX channel with an obvious S-shaped amplification curve (Ct value ≤ 40), no requirements are made for the detection results of the internal standard (VIC) channel.
[0097] Embodiment 5:
[0098] Application of freeze-dried PCR reagents and kits for detection of Mycoplasma pneumoniae nucleic acid and 23S rRNA gene mutation sites in clinical samples
[0099] The reagents used were the freeze-dried PCR reagents and kits (48 portions / box) for detecting Mycoplasma pneumoniae nucleic acid and 23S rRNA gene mutation sites prepared in Example 3, and the samples to be tested were 10 Mycoplasma pneumoniae-positive throat swab samples and 10 Mycoplasma pneumoniae-negative throat swab samples remaining from the hospital laboratory.
[0100] The detection method is the same as in Example 4. The MP positive control and the MP negative control meet the quality control standards, and this detection is valid.
[0101] like Figure 3 The test results are shown in the following table: 2 samples were positive for Mycoplasma pneumoniae without A2063G and / or A2064G mutations; 8 samples were positive for Mycoplasma pneumoniae with A2063G and / or A2064G mutations; 10 samples were negative for Mycoplasma pneumoniae; the test results were consistent with those of the hospital.
[0102]
[0103]
[0104] Embodiment 6:
[0105] Stability testing of freeze-dried PCR reagents and kits for detecting nucleic acid and 23S rRNA gene mutation sites of Mycoplasma pneumoniae
[0106] The kit used in this example is the freeze-dried PCR reagent and kit (48 servings / box) for detecting Mycoplasma pneumoniae nucleic acid and 23S rRNA gene mutation sites prepared in Example 3. The MP positive control and MP negative control were used to detect the freeze-dried PCR kit stored at room temperature for 9 months and the newly prepared freeze-dried PCR kit of the control group (preparation method is the same as Example 3), and the detection method is the same as Example 4.
[0107] like Figure 4 As shown, the amplification performance of the freeze-dried PCR kit stored at room temperature for 9 months is consistent with the amplification performance of the newly prepared freeze-dried PCR kit in the control group. Therefore, the freeze-dried PCR reagent and kit (48 servings / box) for detecting Mycoplasma pneumoniae nucleic acid and 23S rRNA gene mutation sites prepared in Example 3 can be stored at room temperature for 9 months.
[0108] The above shows and describes the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention. The scope of protection of the present invention is defined by the attached claims and their equivalents.
Claims
1. A freeze-dried PCR reagent for nucleic acid and gene mutation site detection, comprising: MP reaction lyophilized powder; MP positive control; MP negative control; The MP reaction freeze-dried powder comprises an optimized buffer system, Taq DNA polymerase, dNTP, and a freeze-drying protective agent; Also included are oligonucleotide upstream primers, oligonucleotide downstream primers and oligonucleotide fluorescent probes for specifically amplifying the P1 gene of Mycoplasma pneumoniae, the sequences of which are SEQ ID NOs: 1-3; An oligonucleotide upstream primer, an oligonucleotide downstream primer and an oligonucleotide fluorescent probe for specifically amplifying a 23S rRNA gene mutation site, the sequences of which are SEQ ID NOs: 4-6; The oligonucleotide upstream primer, oligonucleotide downstream primer and oligonucleotide fluorescent probe for specifically amplifying the β-actin gene on the human genome have sequences of SEQ ID NOs: 7-9.
2. A freeze-dried PCR reagent for nucleic acid and gene mutation site detection according to claim 1, characterized in that: The two ends of the oligonucleotide fluorescent probe are respectively labeled with a fluorescent group and a quenching group, the fluorescent group is one of FAM, VIC, CY5, ROX or other fluorescent groups with luminescent properties, and the quenching group is one of BHQ1, BHQ2, BHQ3, TAMRA, MGB or other chemical groups with fluorescence quenching function.
3. A freeze-dried PCR reagent for nucleic acid and gene mutation site detection according to claim 2, characterized in that: Each tube of the MP reaction lyophilized powder includes: 0.1μM-1μM oligonucleotide upstream primer, 0.1μM-1μM oligonucleotide downstream primer, 0.1μM-1μM oligonucleotide fluorescent probe, 0.1-1 unit Taq DNA polymerase and m / v 1%-10% lyophilization protectant, 0.1-1mM dNTP and optimized 1-10× buffer system.
4. A freeze-dried PCR reagent for nucleic acid and gene mutation site detection according to claim 3, characterized in that: The Taq DNA polymerase is a mutant Taq DNA polymerase, and the Taq DNA polymerase is one of chemically modified, antibody modified, and ligand modified.
5. A freeze-dried PCR reagent for nucleic acid and gene mutation site detection according to claim 4, characterized in that: The lyophilization protective agent is a mixture of one or more of glycine, trehalose, sucrose, gelatin, PEG-20000, hydroxypropyl-β-cyclodextrin, PVP-10000, maltodextrin, sodium carboxymethyl cellulose, etc.
6. A freeze-dried PCR reagent for nucleic acid and gene mutation site detection according to claim 5, characterized in that: The MP reaction lyophilized powder was prepared by the following lyophilization procedure: 0°C, 30 min; -50°C, 3 h; -30°C, 14 bar, 3 h; -10°C, 14 bar, 2 h; 0°C, 14 bar, 1 h; 30°C, 14 bar, 4 h.
7. A freeze-dried PCR reagent for nucleic acid and gene mutation site detection according to claim 6, characterized in that: The MP positive control is a pseudovirus containing a Mycoplasma pneumoniae P1 gene sequence and a 23SrRNA mutation site gene sequence specific fragment, a pseudovirus containing a human β-actin gene specific fragment, and 0.9% saline, wherein the saline contains 0.1ng / μL salmon sperm DNA, and the pseudovirus concentration is 10 5 copies / mL.
8. A freeze-dried PCR reagent for nucleic acid and gene mutation site detection according to claim 7, characterized in that: The MP negative control is a pseudovirus containing a human β-actin gene specific fragment, 0.9% saline, the saline contains 0.1 ng / μL salmon sperm DNA, the pseudovirus concentration is 10 5 copies / mL.
9. A freeze-dried PCR reagent for nucleic acid and gene mutation site detection according to claim 8, characterized in that: The quantitative PCR program of the fluorescent group was set as follows: 95°C pre-denaturation for 30s, 95°C denaturation for 10s, 62°C annealing and extension to collect fluorescence for 13s, and this was repeated for 42 cycles. The P1 gene was detected in the ROX channel, the 23S rRNA gene was detected in the FAM channel, and the human β-actin gene was detected in the VIC channel.
10. A kit for detecting nucleic acids and gene mutation sites, the kit being applicable to the freeze-dried PCR reagent for detecting nucleic acids and gene mutation sites as claimed in any one of claims 1 to 9, the kit being used for MP reaction freeze-dried powder, MP positive control and MP negative control, the kit being provided with multiple components for the entire detection process of sample collection, nucleic acid extraction and amplification detection.
